| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
BRAF mutations in hairy-cell leukemia.
|
N Engl J Med
|
2011
|
7.05
|
|
2
|
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
|
Lancet
|
2010
|
5.59
|
|
3
|
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.
|
J Clin Oncol
|
2007
|
3.99
|
|
4
|
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
|
J Clin Oncol
|
2013
|
3.58
|
|
5
|
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.
|
Blood
|
2011
|
2.71
|
|
6
|
Autologous transplantation and maintenance therapy in multiple myeloma.
|
N Engl J Med
|
2014
|
2.33
|
|
7
|
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
|
Blood
|
2010
|
2.20
|
|
8
|
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.
|
J Clin Oncol
|
2009
|
2.19
|
|
9
|
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
|
J Clin Oncol
|
2007
|
2.14
|
|
10
|
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.
|
Haematologica
|
2003
|
1.97
|
|
11
|
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
|
Blood
|
2011
|
1.96
|
|
12
|
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
|
J Clin Oncol
|
2007
|
1.94
|
|
13
|
Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.
|
Blood
|
2007
|
1.91
|
|
14
|
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
|
Blood
|
2011
|
1.76
|
|
15
|
Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma.
|
Haematologica
|
2002
|
1.69
|
|
16
|
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.
|
Blood
|
2002
|
1.68
|
|
17
|
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.
|
Blood
|
2011
|
1.59
|
|
18
|
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
|
Eur J Haematol
|
2014
|
1.55
|
|
19
|
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.
|
Blood
|
2008
|
1.52
|
|
20
|
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
|
Haematologica
|
2002
|
1.47
|
|
21
|
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
|
J Clin Oncol
|
2014
|
1.44
|
|
22
|
Absolute lymphocyte count is unrelated to overall survival in newly diagnosed elderly patients with multiple myeloma treated with immunomodulatory drugs.
|
Leuk Lymphoma
|
2014
|
1.41
|
|
23
|
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
|
J Clin Oncol
|
2009
|
1.41
|
|
24
|
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol.
|
Blood
|
2005
|
1.39
|
|
25
|
Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors.
|
J Exp Med
|
2004
|
1.37
|
|
26
|
CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
|
Blood
|
2010
|
1.21
|
|
27
|
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
|
J Immunol
|
2010
|
1.20
|
|
28
|
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.
|
Cancer
|
2011
|
1.18
|
|
29
|
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification.
|
Blood
|
2006
|
1.17
|
|
30
|
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
|
Leuk Res
|
2007
|
1.13
|
|
31
|
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
|
J Clin Oncol
|
2014
|
1.10
|
|
32
|
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.
|
Br J Haematol
|
2010
|
1.09
|
|
33
|
Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.
|
Clin Cancer Res
|
2013
|
1.09
|
|
34
|
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
|
Eur J Haematol
|
2009
|
1.07
|
|
35
|
Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival.
|
Haematologica
|
2009
|
1.05
|
|
36
|
Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.
|
Curr Pharm Des
|
2013
|
1.04
|
|
37
|
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107).
|
Br J Haematol
|
2011
|
1.04
|
|
38
|
Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
|
Leuk Res
|
2004
|
1.03
|
|
39
|
Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation.
|
J Bone Miner Metab
|
2009
|
1.02
|
|
40
|
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.
|
Haematologica
|
2013
|
1.01
|
|
41
|
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes.
|
Genes Chromosomes Cancer
|
2010
|
1.01
|
|
42
|
High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.
|
Br J Haematol
|
2014
|
1.00
|
|
43
|
Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.
|
Clin Cancer Res
|
2013
|
0.98
|
|
44
|
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
|
Blood
|
2006
|
0.98
|
|
45
|
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
|
Blood
|
2013
|
0.95
|
|
46
|
Pleuric presentation of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: a case report and a review of the literature.
|
Int J Hematol
|
2010
|
0.95
|
|
47
|
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.
|
Blood
|
2007
|
0.94
|
|
48
|
Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML.
|
Leuk Res
|
2010
|
0.94
|
|
49
|
Effects of imatinib mesylate in osteoblastogenesis.
|
Exp Hematol
|
2009
|
0.94
|
|
50
|
The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial.
|
Haematologica
|
2006
|
0.94
|
|
51
|
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia.
|
Genes Chromosomes Cancer
|
2011
|
0.93
|
|
52
|
GIMEMA ALL - Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia.
|
Haematologica
|
2004
|
0.93
|
|
53
|
Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
|
Clin Cancer Res
|
2013
|
0.92
|
|
54
|
Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.
|
Br J Haematol
|
2014
|
0.92
|
|
55
|
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles.
|
Am J Hematol
|
2012
|
0.92
|
|
56
|
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.
|
Acta Haematol
|
2008
|
0.92
|
|
57
|
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.
|
Blood
|
2002
|
0.91
|
|
58
|
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
|
Blood
|
2011
|
0.91
|
|
59
|
M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience.
|
Haematologica
|
2008
|
0.91
|
|
60
|
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
|
Acta Oncol
|
2010
|
0.90
|
|
61
|
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.
|
Blood
|
2013
|
0.89
|
|
62
|
Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies.
|
Int J Cancer
|
2012
|
0.88
|
|
63
|
Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.
|
Mol Cancer Ther
|
2013
|
0.88
|
|
64
|
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.
|
Hematol Oncol
|
2011
|
0.88
|
|
65
|
E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features.
|
Br J Haematol
|
2003
|
0.88
|
|
66
|
CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia.
|
Leuk Res
|
2009
|
0.87
|
|
67
|
Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia.
|
PLoS One
|
2011
|
0.87
|
|
68
|
Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci.
|
Genes Chromosomes Cancer
|
2010
|
0.86
|
|
69
|
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.
|
Am J Hematol
|
2014
|
0.86
|
|
70
|
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
|
Am J Hematol
|
2014
|
0.85
|
|
71
|
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
|
J Clin Oncol
|
2009
|
0.85
|
|
72
|
Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms.
|
Ann Hematol
|
2009
|
0.84
|
|
73
|
Primary plasma cell leukemia in the era of new drugs: has something changed?
|
Crit Rev Oncol Hematol
|
2011
|
0.84
|
|
74
|
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.
|
Am J Hematol
|
2012
|
0.84
|
|
75
|
Bortezomib for the treatment of previously untreated multiple myeloma.
|
Immunotherapy
|
2013
|
0.83
|
|
76
|
Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.
|
Cancer
|
2003
|
0.82
|
|
77
|
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma.
|
BMC Med Genomics
|
2009
|
0.82
|
|
78
|
GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.
|
Br J Haematol
|
2011
|
0.82
|
|
79
|
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.
|
BMC Cancer
|
2013
|
0.82
|
|
80
|
Amyloid in bone marrow smears of patients affected by multiple myeloma.
|
Ann Hematol
|
2009
|
0.82
|
|
81
|
Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma.
|
Haematologica
|
2012
|
0.81
|
|
82
|
External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia.
|
Cancer
|
2012
|
0.81
|
|
83
|
Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients.
|
Br J Haematol
|
2012
|
0.81
|
|
84
|
NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.
|
Leuk Res
|
2010
|
0.81
|
|
85
|
Vertebroplasty in multiple myeloma with osteolysis or fracture of the posterior vertebral wall. Usefulness of a delayed cement injection.
|
Skeletal Radiol
|
2011
|
0.81
|
|
86
|
Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients.
|
Clin Drug Investig
|
2011
|
0.81
|
|
87
|
Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
|
Br J Haematol
|
2008
|
0.80
|
|
88
|
Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome.
|
Blood
|
2003
|
0.80
|
|
89
|
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.
|
Eur J Haematol
|
2011
|
0.79
|
|
90
|
Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients.
|
Br J Haematol
|
2003
|
0.79
|
|
91
|
Bone turnover markers in patients with type 1 Gaucher disease.
|
Hematol Rep
|
2012
|
0.78
|
|
92
|
Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.
|
Am J Hematol
|
2013
|
0.78
|
|
93
|
Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene.
|
Am J Hematol
|
2011
|
0.78
|
|
94
|
Role of thalidomide in previously untreated patients with multiple myeloma.
|
Expert Rev Anticancer Ther
|
2008
|
0.78
|
|
95
|
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients.
|
Leuk Lymphoma
|
2011
|
0.78
|
|
96
|
The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis.
|
Leuk Res
|
2013
|
0.78
|
|
97
|
Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up.
|
Hematol Oncol
|
2011
|
0.77
|
|
98
|
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia.
|
Acta Haematol
|
2011
|
0.77
|
|
99
|
Double CEBPE-IGH rearrangement due to chromosome duplication and cryptic insertion in an adult with B-cell acute lymphoblastic leukemia.
|
Cancer Genet
|
2011
|
0.77
|
|
100
|
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.
|
FASEB J
|
2013
|
0.77
|
|
101
|
Multidrug resistance mechanisms in chronic lymphocytic leukaemia.
|
Br J Haematol
|
2002
|
0.77
|
|
102
|
Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience.
|
Leuk Res
|
2010
|
0.77
|
|
103
|
Sacroplasty for local or massive localization of multiple myeloma.
|
Cardiovasc Intervent Radiol
|
2009
|
0.77
|
|
104
|
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.
|
Ann Hematol
|
2013
|
0.76
|
|
105
|
Angiogenesis in hematology: a field of active research.
|
Leuk Res
|
2003
|
0.76
|
|
106
|
Lymphoma of the cecum: a case report.
|
Int Surg
|
2002
|
0.76
|
|
107
|
Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?
|
Lancet Oncol
|
2011
|
0.76
|
|
108
|
Aberrant phenotypic expression of the T-cell-associated antigen CD8 on B-cell chronic lymphocytic leukemia cells.
|
Lab Hematol
|
2009
|
0.76
|
|
109
|
Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.
|
Am J Hematol
|
2010
|
0.76
|
|
110
|
Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy.
|
Int J Hematol
|
2012
|
0.76
|
|
111
|
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
|
J Hematol Oncol
|
2013
|
0.76
|
|
112
|
First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective.
|
Curr Drug Targets
|
2009
|
0.76
|
|
113
|
Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study.
|
Br J Haematol
|
2014
|
0.76
|
|
114
|
Diagnosis of blastic phase of chronic myeloid leukemia.
|
Acta Haematol
|
2012
|
0.75
|
|
115
|
Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.
|
Turk J Haematol
|
2015
|
0.75
|
|
116
|
Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment.
|
Leuk Res
|
2012
|
0.75
|
|
117
|
Infliximab therapy in hematologic malignancies: handle with care.
|
Haematologica
|
2012
|
0.75
|
|
118
|
CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.
|
Leuk Res
|
2013
|
0.75
|
|
119
|
Captivating bortezomib: an active but still mysterious drug.
|
Leuk Res
|
2009
|
0.75
|
|
120
|
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts.
|
Eur J Haematol
|
2008
|
0.75
|
|
121
|
A snapshot of asparaginase-induced liver insufficiency.
|
Eur J Haematol
|
2014
|
0.75
|
|
122
|
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas.
|
Leuk Lymphoma
|
2002
|
0.75
|
|
123
|
Intrasomatic injection of corticosteroid followed by vertebroplasty increases early pain relief rather than vertebroplasty alone in vertebral bone neoplasms: preliminary experience.
|
Skeletal Radiol
|
2011
|
0.75
|
|
124
|
Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.
|
Leuk Res
|
2012
|
0.75
|
|
125
|
Uncommon long-term survival in a patient with chronic myeloid leukemia.
|
Acta Oncol
|
2009
|
0.75
|
|
126
|
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.
|
Acta Oncol
|
2010
|
0.75
|
|
127
|
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia.
|
Acta Haematol
|
2010
|
0.75
|
|
128
|
Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: a clinical survey of 5 cases in Catania, Italy.
|
J Clin Virol
|
2011
|
0.75
|
|
129
|
Treatment of newly diagnosed multiple myeloma.
|
Curr Hematol Malig Rep
|
2008
|
0.75
|
|
130
|
Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma.
|
Leuk Lymphoma
|
2010
|
0.75
|
|
131
|
Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.
|
Expert Rev Hematol
|
2013
|
0.75
|
|
132
|
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
|
Carcinogenesis
|
2014
|
0.75
|
|
133
|
Utility of flow cytometry as a screening tool for transplant donors for chronic lymphocytic leukemia.
|
Acta Haematol
|
2010
|
0.75
|